He has provided financial accounting, strategic analysis, audit, and taxation advisory services to public and private companies and facilitated numerous transactions involving debt and equity financings, mergers and acquisitions, corporate re-organizations and divestitures. Löbenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.Get the latest news and press releases straight to your inbox – For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. April 2020) - XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) ("XPhyto" oder das "Unternehmen") freut sich bekannt zu geben, dass XPhytos hundertprozentige deutsche Tochtergesellschaft Vektor Pharma TF GmbH ("Vektor") im Zusammenhang mit ihrer Pressemitteilung vom 20. BUNKER holds a unique German cannabis cultivation and extraction licence for scientific purposes awarded by the German health authority. Preliminary testing will include analysis of the chemical-physical suitability of the cannabis derived materials for use in various food and beverages. Vektor holds a number of valid … XPhyto Therapeutics Corp. acquired 100% of Vektor Pharma TF GmbH, a German narcotics manufacturer, importer, and researcher. to Canadian licenced growers, processors, dispensaries, and government agencies.Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. April 2020 bezüglich einer definitiven Entwicklungs-, Technologiekauf- und Lizenzvereinbarung (die "Vereinbarung") mit 3a-Diagnostics GmbH ("3a"), bestimmte pathogen-spezifische Peptid-Biosensoren von 3a übernommen hat, um sie für die Verwendung mit Vektors oral löslicher Dünnfilm ("ODF")-Plattform anzupassen.Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von XPhyto Therapeutics Corp.: Entwicklung eines oral auflösbaren Biosensors zum Nachweis von InfektionskrankheitenXPHYTO THERAPEUTICS-Aktie komplett kostenlos handeln - auf Smartbroker.deXphyto Therapeutics Corp: Xphyto Therapeutics begins trading on OTCQB For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips for the clinical management of pain. The initial research project will focus on the identification and assessment of novel R&D approaches to utilize the cannabis plant and its derivatives, including cannabinoids, terpenes, terpenoids, polyphenols and flavones. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. XPHYTO THERAPEUTICS AKTIE und aktueller Aktienkurs. You can unsbscribe anytime.This website uses cookies and third party services. Nachrichten zur Aktie XPhyto Therapeutics Corp Registered Shs Reg S | A2PPTN | CA98421R1055 He is a member in good standing of the Law Society of British Columbia.Dr. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.FUNCTION OF COVID-19 RNA PROBES SUCCESSFULLY CONFIRMED IN PROTOTYPE TESTINGBy submitting the form you agree to our privacy policy. Subject to meeting BfArM security requirements, the licence authorizes the Company to cultivate, extract up to 70 different strains of Cannabis sativa and Cannabis indica for scientific purposes. Mr. Ross holds a bachelor’s degree in Commerce (Accounting) and is a member in good standing of the Chartered Professional Accountants Association of British Columbia. 3a refers to their approach as “anyone” (no specialized training required), “anywhere” (no power or additional equipment required) and “anytime” (decentralized and rapidly deployable).XPhyto Therapeutics Corp. acquired 100% of Vektor Pharma TF GmbH, a German narcotics manufacturer, importer, and researcher. Dr. Löbenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis or leishmanasis. Über XPhyto Therapeutics Corp. XPhyto ist ein Cannabisunternehmen der nächsten Generation, das sich auf die Formulierung, die klinische Validierung und die …